| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
184,511 |
159,407 |
$12.99M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
151,924 |
109,146 |
$8.94M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
74,341 |
63,211 |
$7.74M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
110,085 |
78,851 |
$4.51M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
69,090 |
52,053 |
$2.16M |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
111,905 |
52,847 |
$1.30M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
36,793 |
23,507 |
$844K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
62,393 |
53,205 |
$732K |
| 99199 |
Unlisted special service, procedure or report |
136,110 |
130,685 |
$409K |
| 81025 |
|
21,001 |
16,922 |
$124K |
| 81003 |
|
55,465 |
44,361 |
$106K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,860 |
7,120 |
$104K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,328 |
2,076 |
$96K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,253 |
1,570 |
$90K |
| 99215 |
Prolong outpt/office vis |
483 |
453 |
$39K |
| 71046 |
Radiologic examination, chest; 2 views |
1,648 |
1,504 |
$32K |
| 73610 |
|
1,107 |
1,050 |
$23K |
| 99205 |
Prolong outpt/office vis |
170 |
150 |
$20K |
| 73630 |
|
976 |
904 |
$19K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,918 |
1,850 |
$17K |
| 73130 |
|
652 |
613 |
$13K |
| 73110 |
|
582 |
542 |
$13K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
412 |
311 |
$11K |
| 83986 |
|
2,764 |
2,466 |
$10K |
| 93000 |
|
698 |
662 |
$10K |
| 73140 |
|
489 |
457 |
$9K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
901 |
700 |
$7K |
| 73562 |
|
201 |
197 |
$5K |
| 86308 |
|
789 |
763 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
90 |
73 |
$4K |
| 82947 |
|
592 |
566 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
1,131 |
1,022 |
$2K |
| 90674 |
|
162 |
116 |
$1K |
| 12001 |
|
12 |
12 |
$1K |
| 99201 |
|
35 |
24 |
$811.32 |
| 73080 |
|
27 |
25 |
$607.50 |
| 73030 |
|
26 |
25 |
$504.12 |
| 81002 |
|
277 |
263 |
$485.47 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
280 |
262 |
$465.83 |
| 90756 |
|
236 |
212 |
$446.85 |
| 90658 |
|
205 |
123 |
$380.46 |
| 90688 |
|
77 |
54 |
$294.30 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
259 |
246 |
$172.96 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
230 |
216 |
$111.92 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
134 |
129 |
$0.98 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
121 |
113 |
$0.39 |
| S9083 |
Global fee urgent care centers |
160 |
151 |
$0.00 |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
31 |
31 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
52 |
48 |
$0.00 |